ClinicalTrials.gg
CompletedNCT06280391Updated Oct 7, 2026Results posted

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

A Phase 2 interventional study of Itepekimab (SAR440340) and Placebo in Bronchiectasis, sponsored by Sanofi. Completed at 117 sites in 20 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
11th of 52
314 · median 78
Started
2024
with 7 others
Phase 2
15 of 65
4 open now
Registered
50th of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 11th largest by enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2024, is one of 15 in phase 2, and was the 50th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study was to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).

Study details include:

  • The study duration (screening, 24-52-week treatment, 20-week safety follow-up) was up to 47-77 weeks
  • The treatment duration was up to 24-52 weeks
  • The follow-up duration was 20 weeks
  • Site/phone visits were at a monthly interval
03

Conditions studied

  • Bronchiectasis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 85 years of age inclusive
  • Clinical history consistent with NCFB (cough, chronic sputum production and/or recurrent respiratory infections)
  • Participants with a % predicted ≥30%
  • Participants with at least 2 moderate or 1 severe Pulmonary exacerbations (PEs) in the past 12 months

Exclusion criteria

Exclusion Criteria:

Participants were excluded from the study if any of the following criteria apply:

  • Had bronchiectasis due to CF, hypogammaglobulinemia, common variable immunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, or pulmonary fibrosis
  • Known or suspected immunodeficiency disorder
  • Pulmonary exacerbation which had not resolved clinically during screening period
  • Had significant haemoptysis
  • Had any abnormal laboratory values at Screening or diseases or disorders
  • History of lung transplantation
  • History of within 5 years before Screening, or during the screening period
  • Was being treated with antimicrobial therapy for tuberculosis (TB)
  • Was on active treatment for allergic bronchopulmonary aspergillosis (ABPA)
  • Participants with active disease or participants using therapy for autoimmune disease
  • Known allergy to itepekimab or to
  • (s) within 4 weeks prior to Screening or planned to receive such vaccines during the study
  • Unstable ischemic heart disease
  • Cardiomyopathy or other relevant cardiovascular disorder
  • Clinically significant new abnormal (ECG) within 6 months prior to, or at Screening
  • History of (HIV) infection or positive HIV 1/2 serology at Screening

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Itepekimab Q2W

    Participants received itepekimab 300 mg Subcutaneous (SC) injection every 2 weeks (Q2W) for up to 52 weeks

    Drug: Itepekimab (SAR440340)

  • Experimental
    Itepekimab Q4W

    Participants received itepekimab 300 mg SC injection Q4W with alternating placebo matched to itepekimab SC administration at the 2-week interval between active study drug for up to 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants received placebo matched to itepekimab subcutaneous (SC) injection Q2W for up to 52 weeks

    Drug: Placebo

Interventions

  • * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    * Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period

    PEs were recorded by Investigator. Moderate PEs were defined as acute worsening of respiratory symptoms (\>=3 symptoms for \>=48 hours) requiring antibiotic treatment. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. Events separated by \<14 days were considered as single events. All PE events were adjudicated by an independent committee. For both moderate and severe events to be counted as 2 separate events, they were separated by at least 14 days between any course of antibiotics and/or systemic corticosteroids or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.

    Time frame: Baseline (Day 1) up to Week 24 to 52

Secondary outcomes

  1. Time to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period

    Time to first moderate or severe PE was defined as the onset date of the first moderate or severe PE during the observation period (as per endpoint #1) minus (-) randomization date plus (+) 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only).

    Time frame: Baseline (Day 1) up to Week 24 to 52

  2. Percentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period

    PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Percentage of participants who were moderate or severe PE free over the treatment period are reported. Moderate and severe PE as defined in endpoint #1. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) up to Week 24 to 52

  3. Annualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period

    PEs were recorded by Investigator. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. All PE events were adjudicated by an independent committee. Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.

    Time frame: Baseline (Day 1) up to Week 24 to 52

  4. Percentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period

    PEs were defined as an acute worsening of respiratory symptoms) leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE described in endpoint #1 but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death. Percentage of participants who were severe PE free over the treatment period are reported. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) up to Week 24 to 52

  5. Time to First Severe Pulmonary Exacerbation Over the Treatment Period

    Time to first severe PE was defined as the onset date of the first severe PE during the observation period - randomization date + 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death.

    Time frame: Baseline (Day 1) up to Week 24 to 52

  6. Change From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Weeks 8 and 24

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration following the European Respiratory Society/American Thoracic Society 2019 guidance. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.

    Time frame: Baseline (Day 1) and Weeks 8 and 24

  7. Change From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24

    The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.

    Time frame: Baseline (Day 1) and Weeks 8 and 24

  8. Median Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation

    PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Systemic antibiotics used less than 60 days to treat a NCFB exacerbation were considered. Median number of days of new and/or added acute antibiotics used to treat PE in participants with maintenance antibiotic use is reported.

    Time frame: Baseline (Day 1) up to Week 24 to 52

  9. Change From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24

    QOL-B is self-administered patient reported outcome (PRO) that assesses symptoms, functioning and health-related QOL for participants with NCFB; contains 37 items in 8 domains (respiratory symptoms, physical functioning, role functioning, emotional functioning, social functioning, vitality, health perceptions and treatment burden). Respiratory Symptoms domain assesses respiratory symptom-related QOL;includes 9 questions (from 29 to 37 of QOL-B Questionnaire). Each of 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning/ better QOL.Positive change from baseline=improvement in symptoms. Baseline:last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) and Week 24

  10. Change From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24

    SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower score indicates better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.

    Time frame: Baseline (Day 1) and Week 24

  11. Percentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 24

    SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower scores indicate better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Percentages are rounded off to tenth decimal place.

    Time frame: Baseline (Day 1) and Week 24

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug Discontinuation

    AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period.

    Time frame: From first dose of study drug (Day 1) to a maximum of 72 weeks

  13. Serum Concentrations of Itepekimab

    Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

    Time frame: Baseline (Day 1) and Weeks 4, 8, 24, 52, end of treatment (EOT) (Weeks 24-52) and end of study (EOS) (up to Week 72)

  14. Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab

    Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADAs against itepekimab is presented.

    Time frame: From first dose of study drug (Day 1) to a maximum of 72 weeks

07

Results

Posted Oct 7, 2026

Participant flow

This study was conducted at 117 sites in 20 countries. 386 participants were screened from 20-Feb-2024 to 07-Mar-2025 of which 72 were screen failures due to not meeting eligibility criteria. A total of 314 participants with non-cystic fibrosis bronchiectasis (NCFB) were randomized in this study in a 1:1:1 ratio to either receive placebo matched to itepekimab or itepekimab (once every 2 weeks \[Q2W\] or once every 4 weeks \[Q4W\]).

Participant flow — Overall Study
MilestonePlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Started102104108
Randomized and treated102103107
Completed849093
Not completed181415
Withdrew: Adverse event422
Withdrew: Non-compliance with study schedule010
Withdrew: Withdrawal by subject13611
Withdrew: Other141
Withdrew: Randomized but not treated011

Outcome measures

PrimaryAnnualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period

PEs were recorded by Investigator. Moderate PEs were defined as acute worsening of respiratory symptoms (\>=3 symptoms for \>=48 hours) requiring antibiotic treatment. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. Events separated by \<14 days were considered as single events. All PE events were adjudicated by an independent committee. For both moderate and severe events to be counted as 2 separate events, they were separated by at least 14 days between any course of antibiotics and/or systemic corticosteroids or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Number · events per participant year
Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period
events per participant yearPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period1.238 (0.898 to 1.708)1.053 (0.767 to 1.447)1.029 (0.750 to 1.412)
Statistical analysis
  • Placebo vs Itepekimab 300 mg Q4W · Negative binomial regression model · p = 0.3419 · Rate ratio: 0.851 · 90% CI 0.643 to 1.126
  • Placebo vs Itepekimab 300 mg Q2W · Negative binomial regression model · p = 0.2742 · Rate ratio: 0.831 · 90% CI 0.629 to 1.098
SecondaryTime to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period

Time to first moderate or severe PE was defined as the onset date of the first moderate or severe PE during the observation period (as per endpoint #1) minus (-) randomization date plus (+) 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only).

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Median · weeks
Time to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period
weeksPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Time to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period22.0 (17.00 to 33.00)38.1 (27.86 to NA)42.0 (34.86 to NA)
SecondaryPercentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period

PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Percentage of participants who were moderate or severe PE free over the treatment period are reported. Moderate and severe PE as defined in endpoint #1. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period
percentage of participantsPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Percentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period41.250.053.7
SecondaryAnnualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period

PEs were recorded by Investigator. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. All PE events were adjudicated by an independent committee. Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Number · events per participant year
Annualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period
events per participant yearPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Annualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period0.270 (0.131 to 0.556)0.108 (0.047 to 0.247)0.216 (0.105 to 0.444)
SecondaryPercentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period

PEs were defined as an acute worsening of respiratory symptoms) leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE described in endpoint #1 but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death. Percentage of participants who were severe PE free over the treatment period are reported. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period
percentage of participantsPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Percentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period83.394.287.0
SecondaryTime to First Severe Pulmonary Exacerbation Over the Treatment Period

Time to first severe PE was defined as the onset date of the first severe PE during the observation period - randomization date + 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Median · weeks
Time to First Severe Pulmonary Exacerbation Over the Treatment Period
weeksPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Time to First Severe Pulmonary Exacerbation Over the Treatment PeriodNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Weeks 8 and 24

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration following the European Respiratory Society/American Thoracic Society 2019 guidance. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.

Time frame:
Baseline (Day 1) and Weeks 8 and 24
Reported as:
Least squares mean · liters
Change From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Weeks 8 and 24
litersPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Week 8-0.03 ± 0.020.01 ± 0.02-0.02 ± 0.02
Week 24-0.01 ± 0.030.00 ± 0.03-0.04 ± 0.03
SecondaryChange From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24

The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.

Time frame:
Baseline (Day 1) and Weeks 8 and 24
Reported as:
Least squares mean · liters
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24
litersPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Week 8-0.00 ± 0.020.03 ± 0.020.01 ± 0.02
Week 240.00 ± 0.020.02 ± 0.02-0.00 ± 0.02
SecondaryMedian Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation

PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Systemic antibiotics used less than 60 days to treat a NCFB exacerbation were considered. Median number of days of new and/or added acute antibiotics used to treat PE in participants with maintenance antibiotic use is reported.

Time frame:
Baseline (Day 1) up to Week 24 to 52
Reported as:
Median · days
Median Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation
daysPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Median Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation18.00 (3.0 to 56.0)12.50 (4.0 to 40.0)14.50 (3.0 to 52.0)
SecondaryChange From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24

QOL-B is self-administered patient reported outcome (PRO) that assesses symptoms, functioning and health-related QOL for participants with NCFB; contains 37 items in 8 domains (respiratory symptoms, physical functioning, role functioning, emotional functioning, social functioning, vitality, health perceptions and treatment burden). Respiratory Symptoms domain assesses respiratory symptom-related QOL;includes 9 questions (from 29 to 37 of QOL-B Questionnaire). Each of 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning/ better QOL.Positive change from baseline=improvement in symptoms. Baseline:last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24
score on a scalePlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Change From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 244.42 ± 2.546.49 ± 2.395.84 ± 2.40
SecondaryChange From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24

SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower score indicates better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24
score on a scalePlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Change From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24-2.40 ± 2.20-3.72 ± 2.07-5.27 ± 2.09
SecondaryPercentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 24

SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower scores indicate better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Percentages are rounded off to tenth decimal place.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 24
percentage of participantsPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Percentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 2437.241.657.4
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug Discontinuation

AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period.

Time frame:
From first dose of study drug (Day 1) to a maximum of 72 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug Discontinuation
ParticipantsPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
TEAEs848488
TEAESIs323223
TESAEs242016
TEAEs Leading to Permanent Study Drug Discontinuation222
SecondarySerum Concentrations of Itepekimab

Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.

Time frame:
Baseline (Day 1) and Weeks 4, 8, 24, 52, end of treatment (EOT) (Weeks 24-52) and end of study (EOS) (up to Week 72)
Reported as:
Mean · nanogram per milliliter
Serum Concentrations of Itepekimab
nanogram per milliliterItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Baseline (Day 1)0.00 ± 0.000.00 ± 0.00
Week 415851.09 ± 5329.7135653.40 ± 11140.03
Week 822755.35 ± 8591.2350656.86 ± 17264.57
Week 2431375.21 ± 14197.7667857.29 ± 26838.42
Week 5231874.79 ± 12665.5763649.74 ± 28768.37
EOT32840.10 ± 16186.1761647.04 ± 26539.85
EOS3496.34 ± 9047.413783.34 ± 7095.42
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab

Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADAs against itepekimab is presented.

Time frame:
From first dose of study drug (Day 1) to a maximum of 72 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab
ParticipantsItepekimab 300 mg Q4WItepekimab 300 mg Q2W
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab22

Adverse events

Collected over AEs were collected from first dose of study drug (Day 1) to a maximum of 72 weeks. All-cause mortality (death) was assessed from Day 1 up to end of follow-up for each participant, approximately 101 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo3/102 (2.9%)24/102 (23.5%)57/102 (55.9%)
Itepekimab 300 mg Q4W1/103 (1%)20/103 (19.4%)48/103 (46.6%)
Itepekimab 300 mg Q2W1/107 (0.9%)16/107 (15%)60/107 (56.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
BronchiectasisRespiratory, thoracic and mediastinal disorders9/1025/1039/107
PneumoniaInfections and infestations5/1025/1031/107
InfluenzaInfections and infestations2/1020/1030/107
HaemoptysisRespiratory, thoracic and mediastinal disorders2/1022/1031/107
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1022/1030/107
Femur FractureInjury, poisoning and procedural complications1/1022/1031/107
Lower Respiratory Tract InfectionInfections and infestations1/1020/1032/107
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/1020/1032/107
Pneumonia AspirationInfections and infestations1/1020/1030/107
Pneumonia KlebsiellaInfections and infestations1/1020/1030/107
Most frequent other events
Most frequent other events
EventPlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2W
BronchiectasisRespiratory, thoracic and mediastinal disorders30/10229/10326/107
Upper Respiratory Tract InfectionInfections and infestations12/1027/10313/107
NasopharyngitisInfections and infestations9/1026/10312/107
HeadacheNervous system disorders5/1021/1039/107
InfluenzaInfections and infestations7/1021/1034/107
HaemoptysisRespiratory, thoracic and mediastinal disorders7/1025/1034/107
Iron Deficiency AnaemiaBlood and lymphatic system disorders1/1027/1031/107
SinusitisInfections and infestations6/1024/1033/107
PneumoniaInfections and infestations1/1026/1034/107
Injection Site ErythemaGeneral disorders1/1025/1036/107

Baseline characteristics

The randomized population included all participants from screened population who had been allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received.

Age, Continuous
Age, Continuous(years)PlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2WTotal
Mean61.42 ± 13.6461.58 ± 15.0160.22 ± 14.5961.06 ± 14.40
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2WTotal
Female736971213
Male293537101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboItepekimab 300 mg Q4WItepekimab 300 mg Q2WTotal
American Indian or Alaska Native0000
Asian17192056
Native Hawaiian or Other Pacific Islander0011
Black or African American0202
White847982245
More than one race0000
Unknown or Not Reported14510
08

Study locations

117 sites
  • Pulmonary Associates - Phoenix - East McDowell Road- Site Number : 8400012
    Phoenix, Arizona 85006, United States
  • Southern California Institute for Respiratory Diseases- Site Number : 8400002
    Los Angeles, California 90048, United States
  • Allianz Research Institute- Site Number : 8400013
    Westminster, California 92683, United States
  • Allianz Research Institute CO- Site Number : 8400038
    Aurora, Colorado 80014, United States
  • University of Connecticut Health Center- Site Number : 8400020
    Farmington, Connecticut 06032, United States
  • Yale New Haven Hospital- Site Number : 8400065
    New Haven, Connecticut 06510, United States
  • Advanced Pulmonary Research Institute- Site Number : 8400007
    Loxahatchee Groves, Florida 33470, United States
  • High Quality Research- Site Number : 8400047
    Miami, Florida 33184, United States
  • Avanza Medical Research Center- Site Number : 8400018
    Pensacola, Florida 32503, United States
  • Private Practice - Dr. Frank Hull - Plantation- Site Number : 8400010
    Plantation, Florida 33324, United States
  • Northwestern Memorial Hospital- Site Number : 8400043
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center- Site Number : 8400045
    Kansas City, Kansas 66160, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400055
    Ann Arbor, Michigan 48109, United States
  • Pulmonary and Medicine Associates- Site Number : 8400057
    Warren, Michigan 48088, United States
  • Washington University- Site Number : 8400046
    St Louis, Missouri 63110, United States
  • NYU Langone Medical Center- Site Number : 8400032
    New York, New York 10016, United States
  • Southeastern Research Center- Site Number : 8400008
    Winston-Salem, North Carolina 27103, United States
  • Clinical Research Associates of Central PA - Dubois- Site Number : 8400005
    DuBois, Pennsylvania 15801, United States
  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400039
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8400027
    Charleston, South Carolina 29425, United States
  • Metroplex Pulmonary and Sleep Center- Site Number : 8400014
    McKinney, Texas 75069, United States
  • Pioneer Research Solutions, Inc.- Site Number : 8400048
    Sugar Land, Texas 77479, United States
  • The University of Texas Health Center at Tyler- Site Number : 8400053
    Tyler, Texas 75708, United States
  • Investigational Site Number : 0320003
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320008
    Buenos Aires, 1280, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320007
    Córdoba, 5003, Argentina
  • Investigational Site Number : 0320006
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0320005
    San Miguel de Tucumán, 4000, Argentina
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760004
    Porto Alegre, Rio Grande do Sul 91010-006, Brazil
  • Incor - Instituto do Coracao- Site Number : 0760002
    São Paulo, 05403-900, Brazil
  • Investigational Site Number : 1240003
    Guelph, Ontario N1H 6J2, Canada
  • Investigational Site Number : 1240005
    Sherbrooke, Quebec J1H 5N4, Canada
  • Investigational Site Number : 1240001
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number : 1520001
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7500587, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520004
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 1560005
    Beijing, 100020, China
  • Investigational Site Number : 1560008
    Changchun, 130021, China
  • Investigational Site Number : 1560004
    Chengdu, 610041, China
  • Investigational Site Number : 1560001
    Guangzhou, 510120, China
  • Investigational Site Number : 1560007
    Shenyang, 110004, China
  • Investigational Site Number : 1560003
    Xuzhou, 221006, China
  • Investigational Site Number : 2030006
    Český Krumlov, 381 01, Czechia
  • Investigational Site Number : 2030002
    Jindřichův Hradec, 377 01, Czechia
  • Investigational Site Number : 2030004
    Kralupy nad Vltavou, 278 01, Czechia
  • Investigational Site Number : 2030003
    Pilsen, 305 99, Czechia
  • Investigational Site Number : 2030005
    Prague, 190 00, Czechia
  • Investigational Site Number : 2080002
    Aalborg, 9000, Denmark
  • Investigational Site Number : 2080005
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2080004
    Odense, 5000, Denmark
  • Investigational Site Number : 2080001
    Vejle, 7100, Denmark
  • Investigational Site Number : 2500005
    Brest, 29200, France
  • Investigational Site Number : 2500001
    Lyon, 69004, France
  • Investigational Site Number : 2500002
    Montpellier, 34090, France
  • Investigational Site Number : 2500004
    Nice, 06001, France
  • Investigational Site Number : 2500003
    Paris, 75679, France
  • Investigational Site Number : 2500006
    Saint-Herblain, 44800, France
  • Investigational Site Number : 2760005
    Bendorf, 56170, Germany
  • Investigational Site Number : 2760010
    Berlin, 12159, Germany
  • Investigational Site Number : 2760007
    Essen, 45239, Germany
  • Investigational Site Number : 2760003
    Frankfurt, 60596, Germany
  • Investigational Site Number : 2760004
    Lübeck, 23552, Germany
  • Investigational Site Number : 2760011
    Munich, 80337, Germany
  • Investigational Site Number : 3000001
    Ioannina, 455 00, Greece
  • Investigational Site Number : 3000003
    Thessaloniki, 570 10, Greece
  • Investigational Site Number : 3760008
    Ashkelon, 7830604, Israel
  • Investigational Site Number : 3760006
    Haifa, 3436212, Israel
  • Investigational Site Number : 3760003
    Jerusalem, 9103102, Israel
  • Investigational Site Number : 3760001
    Jerusalem, 9112001, Israel
  • Investigational Site Number : 3760002
    Petah Tikva, 4941492, Israel
  • Investigational Site Number : 3760009
    Ramat Gan, 5262100, Israel
  • Investigational Site Number : 3760004
    Rehovot, 7610001, Israel
  • Investigational Site Number : 3760007
    Tel Aviv, 6423906, Israel
  • Investigational Site Number : 3760010
    Tel Aviv, 6789140, Israel
  • Investigational Site Number : 3800001
    Milan, Lombardy 20122, Italy
  • Investigational Site Number : 3800002
    Rozzano, Milano 20089, Italy
  • Investigational Site Number : 3800004
    Palermo, 90127, Italy
  • Investigational Site Number : 3800003
    Pavia, 27100, Italy
  • Investigational Site Number : 3800006
    Reggio Emilia, 42123, Italy
  • Investigational Site Number : 3920002
    Kamogawa, Chiba 296-0041, Japan
  • Investigational Site Number : 3920004
    Himeji, Hyōgo 670-0849, Japan
  • Investigational Site Number : 3920005
    Kiyose, Tokyo 204-8522, Japan
  • Investigational Site Number : 3920001
    Tokyo, 140-8522, Japan
  • Investigational Site Number : 3920003
    Tokyo, 162-8655, Japan
  • Investigational Site Number : 5280002
    Alkmaar, 1815 JD, Netherlands
  • Investigational Site Number : 5280005
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number : 5280004
    Breda, 4818 CK, Netherlands
  • Investigational Site Number : 5280001
    Rotterdam, 3015 CE, Netherlands
  • Investigational Site Number : 5280003
    The Hague, 2545 CH, Netherlands
  • Investigational Site Number : 6160005
    Lodz, Lódzkie 90-153, Poland
  • Investigational Site Number : 6160001
    Bialystok, Podlaskie Voivodeship 15-044, Poland
  • Investigational Site Number : 6160002
    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, Poland
  • Investigational Site Number : 7240007
    Barcelona, Barcelona [Barcelona] 08017, Spain
  • Investigational Site Number : 7240003
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240006
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number : 7240001
    L'Hospitalet de Llobregat, Barcelona [Barcelona] 08907, Spain
  • Investigational Site Number : 7240012
    Girona, Girona [Gerona] 17005, Spain

Showing the first 100 of 117 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Sep 2025, 18 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
Feb 20, 2024
Primary completionActual
Sep 16, 2025
CompletionActual
Feb 2, 2026
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Sites
21 sites removed
Show 21 removed
  • University of Alabama at Birmingham- Site Number : 8400040 · Birmingham, United States
  • Institute Healthcare Assessment- Site Number : 8400037 · San Diego, United States
  • Clever Medical Research- Site Number : 8400001 · Miami, United States
  • My Community Research Center- Site Number : 8400023 · Miami, United States
  • Destiny Research Center- Site Number : 8400049 · Palmetto Bay, United States
  • American Health Research - Charlotte- Site Number : 8400017 · Charlotte, United States
  • Advanced Respiratory and Sleep Medicine - Huntersville- Site Number : 8400009 · Huntersville, United States
  • Temple University Hospital- Site Number : 8400015 · Philadelphia, United States
  • Plano Primary Care Clinic- Site Number : 8400019 · Plano, United States
  • Investigational Site Number : 0320002 · La Plata, Argentina
  • Investigational Site Number : 0320004 · Buenos Aires, Argentina
  • Oncoclínicas UMC- Site Number : 0760007 · Uberlândia, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005 · Porto Alegre, Brazil
  • Investigational Site Number : 1560006 · Shanghai, China
  • Investigational Site Number : 1560002 · Shanghai, China
  • Investigational Site Number : 2760001 · Ahrensburg, Germany
  • Investigational Site Number : 2760009 · Cottbus, Germany
  • Investigational Site Number : 2760002 · Mainz, Germany
  • Investigational Site Number : 6160003 · Lodz, Poland
  • Investigational Site Number : 6160006 · Wejherowo, Poland
  • Investigational Site Number : 8260008 · Norwich, United Kingdom
Oct 7, 2026
Enrollment
312→314
Oct 7, 2026
Eligibility
9 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedParticipants arewere excluded from the study if any of the following criteria apply:
  • EditedHaveHad bronchiectasis due to CF, hypogammaglobulinemia, common variable immunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, or pulmonary fibrosis.
  • EditedPulmonary exacerbation which hashad not resolved clinically during screening period.
  • EditedHaveHad significant haemoptysis.
  • EditedHaveHad any clinically significant abnormal laboratory values at Screening or diseases or disorders.
  • EditedCurrentlyWas being treated with antimicrobial therapy for tuberculosis (TB).
  • EditedCurrentlyWas on active treatment for allergic bronchopulmonary aspergillosis (ABPA).
  • EditedLive-attenuated vaccine(s) within 4 weeks prior to Screening or plansplanned to receive such vaccines during the study
  • EditedThe above information iswas not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAnnualized rateRate of moderateAdjudicated Moderate or severeSevere Pulmonary exacerbationsExacerbations (PEs) overOver the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
Oct 7, 2026
Documents
Secondary outcomes
12 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedTime to first moderateFirst Moderate or severe PE overSevere Pulmonary Exacerbation Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedPercentage of participants who are PE free overParticipants Who Were Pulmonary Exacerbation Free Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedAnnualized rateRate of severe PEs overAdjudicated Severe Pulmonary Exacerbations Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedPercentage of participants who are severe PE free overParticipants Who Were Severe Pulmonary Exacerbation Free Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedTime to first severe PE overFirst Severe Pulmonary Exacerbation Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedChange From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at WeekWeeks 8 and Week 24Time frame: Week 8 and Week 24 → Baseline (Day 1) and Weeks 8 and 24
  • EditedNumberMedian Days of days of newNew and/or addedAdded (in participants with maintenance antibiotic useParticipants With Maintenance Antibiotic Use) antibiotic useAcute Antibiotics Used to Treat Pulmonary ExacerbationTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
  • EditedChange fromFrom Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
  • EditedChange from baselineFrom Baseline in Saint Georges Respiratory Questionnaire (SGRQ total score) Total Score at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
  • EditedPercentage of participants withParticipants With a decrease from baselineDecrease From Baseline of at leastLeast 4 pointsPoints in SGRQ total scoreSaint Georges Respiratory Questionnaire Total Score at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
  • EditedSerum concentrationsConcentrations of itepekimab from baseline to end of studyItepekimabTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks) → Baseline (Day 1) and Weeks 4, 8, 24, 52, end of treatment (EOT) (Weeks 24-52) and end of study (EOS) (up to Week 72)
  • EditedIncidenceNumber of treatmentParticipants With Treatment-emergent antiAnti-itepekimab antibodiesdrug Antibodies (ADA) responses throughout the studyResponse Against ItepekimabTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks) → From first dose of study drug (Day 1) to a maximum of 72 weeks
  • AddedChange From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24Time frame: Baseline (Day 1) and Weeks 8 and 24
  • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug DiscontinuationTime frame: From first dose of study drug (Day 1) to a maximum of 72 weeks
  • RemovedIncidence of TEAEs, AESIs, SAEs, and AEs leading to permanent study treatment discontinuation in the treatment-emergent periodTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    21 sites removed
    Show 21 removed
    • University of Alabama at Birmingham- Site Number : 8400040 · Birmingham, United States
    • Institute Healthcare Assessment- Site Number : 8400037 · San Diego, United States
    • Clever Medical Research- Site Number : 8400001 · Miami, United States
    • My Community Research Center- Site Number : 8400023 · Miami, United States
    • Destiny Research Center- Site Number : 8400049 · Palmetto Bay, United States
    • American Health Research - Charlotte- Site Number : 8400017 · Charlotte, United States
    • Advanced Respiratory and Sleep Medicine - Huntersville- Site Number : 8400009 · Huntersville, United States
    • Temple University Hospital- Site Number : 8400015 · Philadelphia, United States
    • Plano Primary Care Clinic- Site Number : 8400019 · Plano, United States
    • Investigational Site Number : 0320002 · La Plata, Argentina
    • Investigational Site Number : 0320004 · Buenos Aires, Argentina
    • Oncoclínicas UMC- Site Number : 0760007 · Uberlândia, Brazil
    • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005 · Porto Alegre, Brazil
    • Investigational Site Number : 1560006 · Shanghai, China
    • Investigational Site Number : 1560002 · Shanghai, China
    • Investigational Site Number : 2760001 · Ahrensburg, Germany
    • Investigational Site Number : 2760009 · Cottbus, Germany
    • Investigational Site Number : 2760002 · Mainz, Germany
    • Investigational Site Number : 6160003 · Lodz, Poland
    • Investigational Site Number : 6160006 · Wejherowo, Poland
    • Investigational Site Number : 8260008 · Norwich, United Kingdom
    Enrollment 312→314
    Eligibility 9 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedParticipants arewere excluded from the study if any of the following criteria apply:
    • EditedHaveHad bronchiectasis due to CF, hypogammaglobulinemia, common variable immunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, or pulmonary fibrosis.
    • EditedPulmonary exacerbation which hashad not resolved clinically during screening period.
    • EditedHaveHad significant haemoptysis.
    • EditedHaveHad any clinically significant abnormal laboratory values at Screening or diseases or disorders.
    • EditedCurrentlyWas being treated with antimicrobial therapy for tuberculosis (TB).
    • EditedCurrentlyWas on active treatment for allergic bronchopulmonary aspergillosis (ABPA).
    • EditedLive-attenuated vaccine(s) within 4 weeks prior to Screening or plansplanned to receive such vaccines during the study
    • EditedThe above information iswas not intended to contain all considerations relevant to a patientparticipant's potential participation in a clinical trial.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAnnualized rateRate of moderateAdjudicated Moderate or severeSevere Pulmonary exacerbationsExacerbations (PEs) overOver the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    Secondary outcomes 12 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedTime to first moderateFirst Moderate or severe PE overSevere Pulmonary Exacerbation Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedPercentage of participants who are PE free overParticipants Who Were Pulmonary Exacerbation Free Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedAnnualized rateRate of severe PEs overAdjudicated Severe Pulmonary Exacerbations Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedPercentage of participants who are severe PE free overParticipants Who Were Severe Pulmonary Exacerbation Free Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedTime to first severe PE overFirst Severe Pulmonary Exacerbation Over the treatment periodTreatment PeriodTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedChange From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at WeekWeeks 8 and Week 24Time frame: Week 8 and Week 24 → Baseline (Day 1) and Weeks 8 and 24
    • EditedNumberMedian Days of days of newNew and/or addedAdded (in participants with maintenance antibiotic useParticipants With Maintenance Antibiotic Use) antibiotic useAcute Antibiotics Used to Treat Pulmonary ExacerbationTime frame: Baseline up to End of Treatment (EOT) (24-52 weeks) → Baseline (Day 1) up to Week 24 to 52
    • EditedChange fromFrom Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
    • EditedChange from baselineFrom Baseline in Saint Georges Respiratory Questionnaire (SGRQ total score) Total Score at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
    • EditedPercentage of participants withParticipants With a decrease from baselineDecrease From Baseline of at leastLeast 4 pointsPoints in SGRQ total scoreSaint Georges Respiratory Questionnaire Total Score at Week 24Time frame: Week 24 → Baseline (Day 1) and Week 24
    • EditedSerum concentrationsConcentrations of itepekimab from baseline to end of studyItepekimabTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks) → Baseline (Day 1) and Weeks 4, 8, 24, 52, end of treatment (EOT) (Weeks 24-52) and end of study (EOS) (up to Week 72)
    • EditedIncidenceNumber of treatmentParticipants With Treatment-emergent antiAnti-itepekimab antibodiesdrug Antibodies (ADA) responses throughout the studyResponse Against ItepekimabTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks) → From first dose of study drug (Day 1) to a maximum of 72 weeks
    • AddedChange From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24Time frame: Baseline (Day 1) and Weeks 8 and 24
    • AddedNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug DiscontinuationTime frame: From first dose of study drug (Day 1) to a maximum of 72 weeks
    • RemovedIncidence of TEAEs, AESIs, SAEs, and AEs leading to permanent study treatment discontinuation in the treatment-emergent periodTime frame: Baseline up to End of Study (EOS) (44 to 72 weeks)
    + 5 other changes: identifiers, verification date, description, arm descriptions and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06280391
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Feb 20, 2024
Primary completion
Sep 16, 2025
Completion
Feb 2, 2026
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion